title: [Treatment of patients with Graves' ophthalmopathy by immunosuppressive agent and 99Tc-MDP].
abstract: The purpose of this study was to evaluate the efficacy of immunosuppressive agents, 99Tc-MDP and both of them in treating patients with Graves' ophthalmopathy(GO). The efficacy was evaluated by randomized controlled trial involving a total of 66 patients. In 22 patients treated with immunosuppressive agents, the general efficacy rate was 19/22, the incidence rate of serious side-effect was 8/22. In 20 patients treated with 99Tc-MDP, the general efficacy rate was 17/20, the incidence rate of serious side-effect was 2/20. In 24 patients treated with immunosuppressive agents and 99Tc-MDP, the general efficacy rate was 22/24, the incidence rate of serious side-effect was 2/24. The results suggested that in the treatment of Graves' ophthalmopathy, when satisfactory efficacy was obtained, the serious side-effect and 'rebound' of symptom could be avoided by using immunosuppressive agents in combination with 99Tc-MDP.
authors.affiliation: Department of Nuclear Medicine, West China Hospital of Shichuan University, Chengdu 610041. pwmzj@sina.com
authors.forename: Weimin
authors.initials: W
authors.lastname: Pan
authors.forename: Tianzhi
authors.initials: T
authors.lastname: Tan
authors.forename: Quanlin
authors.initials: Q
authors.lastname: Wang
authors.forename: Jianguo
authors.initials: J
authors.lastname: Zheng
mesh_terms: D049970:Graves Ophthalmopathy / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D013669:Technetium Tc 99m Medronate / Q000627:therapeutic use*
chemical_list: D007166:Immunosuppressive Agents; D013669:Technetium Tc 99m Medronate